Mast Therapeutics, Inc. SVRA 深 滬
等待開盤 12-23 09:30:00 美东时间
6.47
+0.420
+6.94%
華盛通- 最 高6.48
- 今 開5.98
- 成交量 172.31万股
- 最 低 5.86
- 昨 收 6.05
- 總市值 11.19亿
- 52周最高 7.005
- 市盈率 靜 --
- 換手率 1.00%
- 52周最低 1.89
- 委 比 -5.08%
- 總股本 1.73亿
- 歷史最高 17.187
- 量 比 0.25
- 振 幅 10.25%
- 歷史最低 0.69
- 每 手 1
- 風險率 1.03%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Savara Resubmits MOLBREEVI BLA To FDA, With Fujifilm As Drug Substance Manufacturer
-- The BLA was Resubmitted with FUJIFILM Biotechnologies (Fujifilm) as the Drug Substance Manufacturer and Priority Review was Requested --Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical
12-22 21:38
美股大行评级 | 潜在涨幅101%！12家机构集体上调美光目标价；Insmed、RPM、Vital Farms等遭多家大行下调评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从22美元升至22.5美元；HC Wainwright & Co.：维持Climb Bio"买入"评级，目标价从9美元升至11美元
12-19 10:15
Wells Fargo Maintains Overweight on Savara, Raises Price Target to $9
Wells Fargo analyst Benjamin Burnett maintains Savara (NASDAQ:SVRA) with a Overweight and raises the price target from $7 to $9.
12-18 22:54
European Patent Office Intends To Grant Savara Patent For Liquid Formulation Of MOLBREEVI
-- Once Granted, the Patent Will Provide Protection for MOLBREEVI in Europe Until March 2041 ---- Savara Was Also Recently Granted a European Patent Covering the Investigational Drug-Device Combination of MOLBREEVI
12-11 21:16
Savara Inc. ticks higher amid takeover speculation
Savara Inc. (SVRA) pared a loss and ticked higher by 0.2% amid takeover speculation. There's speculation that Savara may have attracted takeover interest, according to traders, who cited a Betaville ...
12-03 03:39
Micron, Endeavour Silver, First Majestic Silver, Applied Digital And Other Big Stocks Moving Higher On Friday
U.S. stocks were higher, with the Dow Jones gaining around 300 points on Friday...
11-29 00:19
美股大行评级 | 花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级
花旗上调Bilibili目标价升至27美元； 摩根士丹利上调英伟达目标价升至220美元；Ardent Health、Stubhub遭多家大行下调评级>>
11-17 10:49
Oppenheimer Maintains Outperform on Savara, Raises Price Target to $9
Oppenheimer analyst Andreas Argyrides maintains Savara (NASDAQ:SVRA) with a Outperform and raises the price target from $8 to $9.
11-15 01:30
Savara Q3 EPS $(0.14) Misses $(0.13) Estimate
Savara (NASDAQ:SVRA) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.13) by 5.26 percent. This is a 27.27 percent decrease over losses of $(0.11) per share from the same
11-13 05:21
Savara Hit with Class Action Over Molbreevi Misrepresentations
Aclass actionlawsuit was filed againstSavara Inc. ($SVRA) on ...
11-04 14:29
